Ізраїль - іврит - Ministry of Health

medomie pharma ltd, israel - bortezomib - אבקה להכנת תמיסה לזריקה - bortezomib 3.5 mg/vial - bortezomib

Ізраїль - іврит - Ministry of Health

neopharm (israel) 1996 ltd - bortezomib - אבקה להכנת תמיסה לזריקה - bortezomib 3.5 mg/vial - bortezomib

Ізраїль - іврит - Ministry of Health

j-c health care ltd - bortezomib 1 mg - powder for solution for injection - bortezomib - velcade (bortezomib) for injection is indicated for the treatment of patients with multiple myeloma. velcade (bortezomib) for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least one prior therapy.

Ізраїль - іврит - Ministry of Health

j-c health care ltd - daratumumab - תרכיז להכנת תמיסה לאינפוזיה - daratumumab 20 mg / 1 ml - daratumumab

Ізраїль - іврит - Ministry of Health

j-c health care ltd - daratumumab - תמיסה להזרקה - daratumumab 120 mg / 1 ml - daratumumab

Ізраїль - іврит - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Ізраїль - іврит - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 5 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Ізраїль - іврит - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Ізраїль - іврит - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 10 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.

Ізраїль - іврит - Ministry of Health

neopharm scientific ltd - lenalidomide - קפסולה קשיחה - lenalidomide 15 mg - lenalidomide - lenalidomide - 1. treatment of patients with transfusion-dependent anemia due to low- or intermediate - 1 - risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormality. 2. in combination with dexamethasone treatment of multiple myeloma patient who have received at least one prior therapy.